This compared to 13% (2/19) for Cau which was similar to the 14.3 % expected value. We also evaluated ALT, AST, albumin, platelet and AST/Platlet Ratio (APRI) to reduce number of false positive patients. The best result to reduce the number of false positives was the APRI (8 patients had a score >1 meaning the false positive rate was 8/131= 6% instead of 33%). Conclusions: The FSII assay overestimates fibrosis in 1/3 of AA with CHC and thus, while it can be used to define minimal fibrosis, it must be used with caution in AA patients

with a high value since they may not have significant fibrosis. The majority of the false positive AA patients have an APRI value less than 1 and their fibrosis can be defined as minimal without subjecting the patients Tamoxifen price to a subsequent biopsy. Disclosures: Paul Naylor – Grant/Research Support: Gilead Sciences Milton G. Mutchnick – Grant/Research Support: Janssen, Gilead; Speaking and Teaching: Janssen, Gilead, Genentech, CLDF, Simply Speaking The NVP-BKM120 molecular weight following people have nothing to disclose: Maher Tama, Suhag Patel, Dhiraj Gulati, Johnny Altawil, Karthik Ravindran, Murray N. Ehrinpreis Objective: Menopause in HCV-positive women

is associated with faster fibrosis progression and resistance to antiviral therapy. As ovarian exhaustion could negatively influence the natural history of fertile women with Hepatitis C, we investigated ovarian function by testing anti-mullerian hormone (AMH), a sensitive indicator of ovarian senescence. Methods: A total of 208 fertile women matched by age (82 controls, 82 HCV+, 44 HBV+) were studied.

HCV+ and HBV+ patients had F2-F3 CLD, none had cirrhosis. AMH and IGF-1 levels were measured by ELISA (AMH Gen II ELISA Beckman Verteporfin research buy Coulter Inc, US); IGF1: R&D, US). Data were analyzed with Fisher’s exact test and the nonparametric Mann-Whitney U test, as appropriate. Results: Mean age of the 3 groups was about 36±7 years. Severity of liver disease was similar (HCV: 6.0±3.0 kPa vs. HBV: 5.9±2.2 kPa, p=0.944). Mean AMH levels were significantly lower in both HCV+ and HBV+ women of child-bearing age (3.2±3 and 2.8±1.6 ng/ml, respectively) vs. controls (13±7ng/ml)(p<0.0001 and p=0.003 respectively). However, HCV+ women had significantly more often AMH levels indicative of ovarian failure (i.e. <0.8 ng/ml) than controls (HCV: 23/82; 28.0% vs. controls: 9/82 (9.7; p<0.0001) or than HBV+ women: 4/44 (9.0%)(p=0.0075). HCV+ women also had a significantly higher number of miscarriages than HBV+ (25/82, 30.4% vs. 5/44, 11.4%, p=0.031). Liver stiffness was significantly higher in HCV+ women with failing AMH levels (failing/normal: 7.3±4.0 vs. 5.6±2.0 ng/ml, p=0.007) but not in HBV+ (failing/normal: 5.8±0.7 vs.6.1±2.3, NS). SVR after Peg IFN/Riba/PI occurred in 37.5% of HCV+ women with failing AMH levels vs. 79.6% of those with normal AMH.